Free Trial

Vaccine And Commodity Concerns Weigh

AUDNZD

AUD/NZD lower in early Asia, last down 18 pips as pressure builds on AUD. Rate last changes hands at 1.0695.

The sell-off is partly attributed to some concern over the efficacy of the AstraZeneca COVID-19 vaccine, Australia has secured 1.2m doses of the vaccine for February, with expectations of a further 1.6m more. In Germany the immunisation commission the vaccine should only be recommended for people between the ages of 18 and 64 with worries of its effectiveness in over 65's.

  • Lower iron ore is also weighing on AUD, in Singapore futures are down around 0.62% after dropping over 5.5% yesterday. If the close is negative today it will denote the seventh down day in the previous nine.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.